The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
Abstract
Purpose: To examine the importance of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER-2), and constructed subtypes in a large study randomly assigning patients to receive or not receive postmastectomy radiotherapy (PMRT). Patients and Methods: The present analysis included 1,000 of the 3,083 high-risk breast cancer patients randomly assigned to PMRT in the Danish Breast Cancer Cooperative Group (DBCG) protocol 82 trials b and c. Tissue microarray sections were stained for ER, PgR, and HER-2. Median follow-up time for patients alive was 17 years. End points were locoregional recurrence as isolated first event, distant metastases, and overall survival. For statistical analyses four subgroups were constructed from hormonal receptors (Rec). Rec+ was defined as ER+ and/or PgR+. Rec–as both ER–and PgR–. The four subgroups were Rec+/HER-2–, Rec+/HER-2+, Rec–/HER-2–(triple negative), and Rec–/HER-2+. Results: A significantly improved overall survival after PMRT was seen only among patients characterized by good prognostic markers such as hormonal receptor–positive and HER-2− patients (including the two Rec+ subtypes). No significant overall survival improvement after PMRT was found among patients with an a priori poor prognosis, the hormonal receptor–negative and HER-2+ patients, and in particular the Rec–/HER-2+ subtype. Furthermore, comparing hazard ratios and 95% CIs, significantly smaller improvements in locoregional recurrence control after PMRT were found for ER–and PgR–tumors compared with the ER+ and PgR+ tumors (P = .003 and .04, respectively), and for the triple-negative (P = .02), and the Rec–/HER-2+ subtypes (P = .003) compared with the Rec+/HER-2–subtype. Conclusion: Hormonal receptor status, HER-2, and the constructed subtypes may be predictive of locoregional recurrence and survival after postmastectomy radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., Kjaer, M., Gadeberg, C. C., Mouridsen, H. T., Jensen, M.-B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371401 · Cited by 2,554
Self-citationFocan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Self-citationAdjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Paradis, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371402 · Cited by 1,745
Overgaard, M., Jensen, M.-B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., Kamby, C., Kjaer, M., Gadeberg, C. C., Rasmussen, B. B., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09201-0 · Cited by 1,602
Self-citationCombination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., De Lena, M., Tancini, G., Bajetta, E., Musumeci, R., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602192940801 · Cited by 1,329
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,084
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Weir, L., Gelmon, K., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh297 · Cited by 1,027
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., Fleming, G. F., Formenti, S., Hudis, C., Kirshner, J. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1539 · Cited by 816
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Wood, W. C., Senn, H.-J., Glick, J. H., & Gelber, R. D. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1441 · Cited by 689
Owens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints
Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Köchli, O. R., Mross, F., Dieterich, H., Moch, H., Mihatsch, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63075-1 · Cited by 566
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
Yaziji, H. (2004) · JAMA · doi:10.1001/jama.291.16.1972 · Cited by 438
Overgaard, M., Nielsen, H. M., & Overgaard, J. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.02.001 · Cited by 438
Self-citationKarnofsky Memorial Lecture. Natural history of small breast cancers.
Hellman, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2229 · Cited by 418
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., & Senn, H.-J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1601 · Cited by 380
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999) · PubMed · Cited by 353
Nielsen, H. M., Overgaard, M., Grau, C., Jensen, A. R., & Overgaard, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8738 · Cited by 347
Self-citationRodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., & Palacios, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2281 · Cited by 324
Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdóttir, K., Olsen, K. E., Mouridsen, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.007 · Cited by 320
Self-citationYamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Consensus statement on postmastectomy radiation therapy
Harris, J. R., Halpin-Murphy, P., McNeese, M., Mendenhall, N. P., Morrow, M., & Robert, N. J. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00096-6 · Cited by 277
Ross, J. S., & Fletcher, J. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-4-237 · Cited by 260
Tissue microarrays (TMAs) for high-throughput molecular pathology research
Nocito, A., Kononen, J., Kallioniemi, O., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1385 · Cited by 242
Zhang, D., Salto-Tellez, M., Putti, T. C., Do, E., & Koay, E. S.-C. (2003) · Modern Pathology · doi:10.1097/01.mp.0000047307.96344.93 · Cited by 179
Hamilton, A., & Piccart, M. (2000) · Annals of Oncology · doi:10.1023/a:1008390429428 · Cited by 174
Anderson, W. F., Chu, K. C., Chatterjee, N., Brawley, O. W., & Brinton, L. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.18 · Cited by 140
Hutchins, L. F., Green, S., Ravdin, P. M., Lew, D. L., Martino, S., Abeloff, M. D., Lyss, A. P., Allred, C. D., Rivkin, S. E., & Osborne, C. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.071 · Cited by 131
Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., Andersen, J., & Overgaard, J. (2008) · Acta Oncologica · doi:10.1080/02841860701851871 · Cited by 74
Self-citationPirollo, K. F., Tong, Y. A., Villegas, Z., Chen, Y., & Chang, E. H. (1993) · Radiation Research · doi:10.2307/3578300 · Cited by 56
Piccart, M. J., Leo, A. D., & Hamilton, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00162-3 · Cited by 53
Ovarian Ablation as Adjuvant Therapy for Breast Cancer
Davidson, N. E. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003464 · Cited by 44
Cited by
Regional Nodal Irradiation in Early-Stage Breast Cancer
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., Vallis, K. A., White, J. R., Rousseau, P., Fortin, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415340 · Cited by 1,294
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9284 · Cited by 1,243
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Metadata
- Authors
- Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., & Overgaard, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-03-20
- Volume
- 26
- Issue
- 9
- Pages
- 1419-1426
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140978771
- Cited by
- 568
- References
- 50
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.